Skip to content

Posts tagged ‘monoclonal antibodies’

Industry and academia – stronger together

Derived from proteins made by the body’s immune system, monoclonal antibodies are successful drugs used to treat millions of patients. The MRC/UCB Antibody Discovery Initiative offers academic researchers access to UCB’s high-tech antibody discovery platform. Andrew Popplewell, Head of Antibody Discovery and Engineering at UCB Celltech, explains how the initiative is geared to help promote collaborative research.

Andrew Popplewell

Image credit: Andrew Popplewell.

In the pharmaceutical and biotechnology industry today, collaboration and networking are all-important. And the value of tapping into academic knowledge, expertise, and talent is widely acknowledged.

Read more

From tool to therapy: a timeline of monoclonal antibody technology

They started out as a useful tool for studying the immune system in the lab and now they’re a family of drugs treating millions of patients, with global revenues of nearly $75 billion in 2013. MRC funding and researchers have been entwined with the monoclonal antibodies story from the very beginning. Forty years ago this month, Nature published a paper by César Milstein and Georges Köhler which described how they’d made mouse monoclonal antibodies. Here we look at the landmarks on the 40-year journey.

They can fight disease, determine blood types, and diagnose pregnancy in minutes. Such varied uses, but the usefulness of monoclonal antibodies actually lies in their uniformity.

Antibodies are proteins that recognise and fight foreign invaders, such as bacteria or viruses. Monoclonal antibodies are tailored in the lab to recognise specific desirable targets, such as a marker on a cancer cell or a pregnancy hormone. They are then churned out in their identical multitudes, ready to become a drug, a diagnostic test, or a probe to study disease in the lab. Read more

Behind the picture: Campath and cake

Think that baking science-themed cakes is a modern phenomenon? Think again. Here Dr Lara Marks explains the story behind this cake baked to celebrate the opening of the Therapeutic Antibody Centre, a small facility which brought the world the first humanised monoclonal antibody drug. The centre features in a new online exhibition which tells the story of that drug, Campath. 

(Image copyright: Geoff Hale*)

(Image copyright: Geoff Hale)

This photograph, taken in 1990, shows a cake baked by research technician Jenny Phillips to commemorate the official opening of the Therapeutic Antibody Centre (TAC) in Cambridge in September of that year.

Supported by funds from the MRC, the purpose of the centre was to manufacture monoclonal antibodies (mAbs), a new type of drug which had been developed in Cambridge a couple of years earlier. There are now more than 30 mAb therapies on the market and approximately 300 mAbs are currently in clinical trials. In 1990, however, the drugs were still very much at an experimental stage, and the aim of the centre was to produce small amounts of mAbs for pilot clinical trials. Read more